<DOC>
	<DOCNO>NCT02418273</DOCNO>
	<brief_summary>The purpose study evaluate denosumab novel treatment bone loss child treat glucocorticoid rheumatic disorder . This pilot Phase 1/2 , randomize open-label , 12-month clinical trial denosumab ass effect bone resorption marker bone mineral density ( BMD ) child rheumatic disorder , age 4 16 year , recruit within 1 month start chronic systemic glucocorticoid regimen . Primary outcome include suppression bone turnover marker safety assessment . Secondary outcome include change bone density measure dual energy X-ray absorptiometry ( DXA ) peripheral quantitative compute tomography ( pQCT ) densitometry radius tibia .</brief_summary>
	<brief_title>Denosumab Glucocorticoid-treated Children With Rheumatic Disorders</brief_title>
	<detailed_description>The purpose study evaluate denosumab novel treatment bone loss child treat glucocorticoid rheumatic disorder . Children rheumatic disorder risk low bone density fracture inflammatory effect underlie disease , also direct effect glucocorticoids bone . This pilot Phase 1/2 , randomize open-label , 12-month clinical trial denosumab ass effect bone resorption marker BMD child rheumatic disorder , age 4 16 year , recruit within 1 month start chronic systemic glucocorticoid regimen . Two different sequential dos administer intervention group evaluation safety efficacy conduct study visit . Primary outcome include suppression bone turnover marker safety assessment . Secondary outcome include change bone density measure dual energy X-ray absorptiometry ( DXA ) peripheral quantitative compute tomography ( pQCT ) densitometry radius tibia .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1 . Age 4 16 year age . 2 . Diagnosis one follow rheumatologist use standard criterion : juvenile dermatomyositis , juvenile idiopathic arthritis , systemic arthritis , seronegative seropositive polyarthritis , psoriatic arthritis , systemic lupus systemic vasculitis . 3 . Within 1 month initiate glucocorticoid ≥0.5 mg/kg prednisone equivalent daily , plan ≥ 6 month . 4 . BMD DXA Zscore &lt; 0.0 screen lumbar spine total body less head ( TBLH ) . 1 . Previous treatment bisphosphonate , osteoporosis medication . 2 . Metabolic bone disorder besides glucocorticoidinduced osteoporosis ; disorder treat systemic glucocorticoid ( inflammatory bowel disease , severe pulmonary disease , nephrotic syndrome , etc. ) . 3 . Intent treat tumor necrosis factor inhibitor Interleukin 6 receptor antagonist first 6 month . 4 . Glomerular filtration rate &lt; 30ml/min [ pediatric estimate glomerular filtration rate = 0.413* ( height/serum creatinine ) ] 75 5 . Planned orthopedic major surgery course study ( time enrollment ) 6 . Significant dental caries , plan undergo invasive oral procedure subsequent 12 month . 7 . Known allergy latex ( drug packaging include natural rubber stopper ) , fructose intolerance denosumab contraindication . 8 . 25hydroxyvitamin D ( 25OHD ) level &lt; 32 ng/dl . Subjects 25OHD &lt; 32 ng/ml may give cholecalciferol rescreened . 9 . Hypocalcemia screening ( total serum calcium &lt; 8.5 mg/dl correction albumin level ) . 10 . Chronic ventilator dependence , condition increase risk participation . 11 . Pregnancy , refusal use acceptable contraception abstain protocol ( postpubertal female ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>denosumab</keyword>
	<keyword>pediatric</keyword>
	<keyword>rheumatology</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>glucocorticoid</keyword>
</DOC>